化合物Valbenazine T7147

Product Introduction
Bioactivity


英文名: Valbenazine

描述: Valbenazine (NBI-98854) 是一种高度选择性的囊泡单胺转运蛋白 2 (VMAT2) 抑制剂，Ki 为 110-190 nM，用于治疗迟发性运动障碍。

动物实验: The pooled long-term exposure (LTE) population included valbenazine-treated subjects from 3 studies: KINECT; KINECT 3; KINECT4. Safety assessments included adverse events (AEs), laboratory tests, vital signs, electrocardiograms (ECGs), and extrapyramidal symptom (EPS) scales. Psychiatric stability was monitored using the Positive and Negative Syndrome Scale (PANSS) and Calgary Depression Scale for Schizophrenia (CDSS) (SCHZ subgroup), as well as the Montgomery-?sberg Depression Rating Scale (MADRS) and Young Mania Rating Scale (YMRS) (mood subgroup). All data were analyzed descriptively[1].

体内活性: Valbenazine 在接受长达48周治疗的成年TD患者中似乎具有良好的耐受性。除了长期疗效结果外，还表明Valbenazine可能适用于长期管理TD，无论患者的基础精神疾病诊断为何（SCHZ disorder或mood disorder）[1]。

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 50 mg/mL (119.45 mM)


关键字: disease | VMAT2 | NBI 98854 | Monoamine Transporter | monoamine | transporter | inhibit | Huntington | Inhibitor | vesicular | Valbenazine | NBI98854

相关产品: Tetrabenazine Metabolite | Valbenazine tosylate | (+)-Tetrabenazine | Tetrabenazine | NBI-98782 | Tetrabenazine Racemate | Diclofensine | Nisoxetine hydrochloride | Reserpine | Xanthoangelol

相关库: FDA-Approved Drug Library | Drug Repurposing Compound Library | Approved Drug Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | Inhibitor Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Approved Drug Library

化合物Valbenazine T7147信息由TargetMol中国为您提供，如您想了解更多关于化合物Valbenazine T7147报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途